Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psychiatry/Bipolar Depression

Bipolar Depression

7

Pipeline Programs↗

16

Active Trials↗

11

Companies Involved↗

Bipolar Depression is an early-stage landscape with 7 programs across 11 companies. The most active players are Xenon Pharmaceuticals Inc.. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

19/100

Mech. Concentration

33/100

Completion Rate

78/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Xenon Pharmaceuticals Inc.

1 program

Pipeline

Programs by Phase

Preclinical1

Same

Indiana University

Phase 11

Psilocybin

COMPASS Pathways

Phase 22

OSU6162

Göteborg University

Ibuprofen

Kenvue Brands

Phase 33

Azetukalner

Xenon Pharmaceuticals Inc.

Cannabidiol

Jazz Pharmaceuticals

Aripiprazole/escitalopram Combination

Massachusetts General Hospital

Approved

No programs

Analysis

Trial Status

114

clinical trials

Completed70 · 61%

Terminated14 · 12%

Recruiting11 · 10%

Unknown status8 · 7%

Withdrawn6 · 5%

Active, not recruiting2 · 2%

Other3 · 3%

Clinical Trials

Trial Activity

114 trials

OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)

Recruiting·GGöteborg University·Phase 2·NCT05296356·22 enrolled

The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression

Recruiting·MMassachusetts General Hospital·Approved·NCT07699445·25 enrolled

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years

Recruiting·IIntra-Cellular Therapies, Inc.·Phase 3·NCT06372964·384 enrolled

Low-Dose Adjunctive Brexpiprazole in the Treatment of Bipolar I Depression: An Open-Label Study

Recruiting·DDouglas Mental Health University Institute·Phase 3·NCT04569448·58 enrolled

Ketogenic Intervention for Bipolar Depression: An Open-Label Trial Guiding Clinical Implementation (KETO-MAYO)

Recruiting·MMayo Clinic·Preclinical·NCT07121894·30 enrolled

Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)

Recruiting·—·Phase 4·NCT05913947·122 enrolled

A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression

Recruiting·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 3·NCT03423680·390 enrolled

Cannabidiol for Bipolar Depression (CBD-BD)

Recruiting·UUniversity of British Columbia·Phase 3·NCT05867849·360 enrolled

HD-tDCS for Adolescent Bipolar Depression Targeting S1

Recruiting·JJiangsu Province Nanjing Brain Hospital·N/A·NCT07246044·100 enrolled

Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

Recruiting·LLaureate Institute for Brain Research, Inc.·Phase 1/2·NCT06088732·20 enrolled

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03522545·30 enrolled

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study

Active, not recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06506019·30 enrolled

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Active, not recruiting·MMassachusetts General Hospital·Phase 4·NCT06433635·2,726 enrolled

Dopamine D3 Receptor Occupancy in Bipolar Depression

Not yet recruiting·NNew York State Psychiatric Institute·Phase 4·NCT05060549·8 enrolled

Empagliflozin Adjunctive Therapy in Bipolar Depression

Not yet recruiting·UUniversity of Sao Paulo·N/A·NCT07472920·20 enrolled

Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)